—
C+
C+ The full Closelook — membership. Open the C+ overview

Medpace Holdings Inc (MEDP) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — Medpace Holdings Inc

MEDP in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Medpace runs clinical trials on behalf of drug and device makers, covering everything from early human-safety studies through to post-marketing follow-up. It designs trial protocols, manages regulatory filings, monitors sites, and analyses the resulting data across many disease areas. The company also runs its own laboratory, imaging and cardiac-monitoring services that feed straight into those trials. It is based in Cincinnati and serves pharmaceutical, biotechnology and medical-device sponsors worldwide.
Where it sits in the stack
Medpace carries no seat in Closelook's index. Inside our universe it sits in the Healthcare sector, grouped with US-listed diagnostics-and-research names for scoring rather than placed against any build-out layer.
Who it is priced against
Closelook's peer group groups it with other scored US healthcare names, chosen by sector and country rather than by business model — argenx, BeiGene, Globus Medical, Regeneron, Veeva Systems, Vertex, Corcept Therapeutics and IDEXX Laboratories. The market also names IQVIA as a comparable contract-research operator.
Why Closelook tracks it
Medpace carries a Closelook score, with momentum the strongest module and valuation the weakest; it holds no index seat and has not yet drawn a quote in the diary's editions.
What the diary watches
The diary watches whether momentum holds as the shares sit some way below their high, and whether the valuation gap to the rest of Closelook's Healthcare peer group narrows or widens from here.

Medpace Holdings Inc (MEDP) trades on US exchanges, classified under Healthcare.

The Closelook company score reads 63/100 composite (momentum 86, quality 74, valuation 29) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for MEDP, from the same nightly bakes the boards use. Research diary readings, not advice.

Who it is priced against Diagnostics & Research · US · 8 names with week and year-to-date

Peer group

Diagnostics & Research · US

Names in the same industry from the Closelook universe; scored names rank on their Closelook score, the rest on trend state.

Compared against MEDP on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

Dividends and capital return no distribution in twelve months · buybacks 917 m USD in FY2025

Dividends and capital return

What MEDP pays out and buys back — distributions read from the price series, money terms from the filings.

  • Distributions No cash distribution recorded in the price series over the last three years
  • Buybacks, FY2025 917 m USD 5.5% of today's market value
  • Share count −7.8% in FY2025 35 m USD of stock-based compensation in the year
  • Capital returned 917 m USD · 135% of free cash flow dividends and buybacks together, against the year’s free cash flow

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 50/100 · S&P 500 fund at 49, above its 50- and 200-day averagesEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-18
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 97th percentile of the window, +4.9% over 20 sessions. Factor regime → 2026-09-18
  • Sector × region Health care in US: +1.8% week · −4.1% month · +13.2% quarter · +8.1% yearThe Sector Engine cell this name lives in, from XLV.US; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-09-20
  • Sovereign pressure Index 0.07 · down 0.41 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-18

FAQ · from the current data · as of 2026-09-19

Quick answers

What is Medpace Holdings Inc (MEDP)?

Medpace Holdings Inc trades as MEDP on the US exchange (US) and is classified under Healthcare in the Closelook research universe, as of the registry build of 2026-09-19.

Is MEDP in a Closelook index?

Not currently — Medpace Holdings Inc is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-19.

What is Medpace Holdings Inc's Closelook composite score?

63 out of 100, with momentum 86, quality 74 and valuation 29 sub-scores, as of 2026-09-19. Scores are Closelook's own research readings, not ratings or investment advice.

Where does MEDP trade against its moving averages?

Uptrend stack intact: Trades +4.7% vs the 50-day and +17.5% vs the 200-day average, 9.7% below the 52-week high and +64.2% off the 52-week low; a golden cross printed 30 sessions ago. Computed from daily closes. As of 2026-09-18 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does Medpace Holdings Inc do?

Medpace runs clinical trials on behalf of drug and device makers, covering everything from early human-safety studies through to post-marketing follow-up. It designs trial protocols, manages regulatory filings, monitors sites, and analyses the resulting data across many disease areas. The company also runs its own laboratory, imaging and cardiac-monitoring services that feed straight into those trials. Closelook's peer group groups it with other scored US healthcare names, chosen by sector and country rather than by business model — argenx, BeiGene, Globus Medical, Regeneron, Veeva Systems, Vertex, Corcept Therapeutics and IDEXX Laboratories. The market also names IQVIA as a comparable contract-research operator.

Where does Medpace Holdings Inc sit in the AI build-out?

Medpace carries no seat in Closelook's index. Inside our universe it sits in the Healthcare sector, grouped with US-listed diagnostics-and-research names for scoring rather than placed against any build-out layer. Medpace carries a Closelook score, with momentum the strongest module and valuation the weakest; it holds no index seat and has not yet drawn a quote in the diary's editions.

Does Medpace Holdings Inc pay a dividend?

No cash distribution shows in Medpace Holdings Inc’s price series over the last three years. In fiscal 2025 the company bought back 917 m USD of its own shares, 135% of that year’s free cash flow. The share count fell 7.8% over the fiscal year. The "Dividends and capital return" block on this page carries the lines.

What does this page show?

A live price chart with SMA overlays and drawing tools for MEDP, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe

then Diagnostics & Research. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.